… direct thrombin inhibitor activity for dabigatran. Studies were excluded if they concerned
review papers, meta-analyses, case reports or series, non-English articles, poster presentations, …

… Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations
of … Dabigatran etexilate, a direct oral thrombin inhibitor, is effective for the treatment and …

… This review aims to application of Dabigatran etexilate in … and disposition of the oral direct
thrombin inhibitor, dabigatran, in … , pharmacokinetics, and pharmacodynamics of dabigatran …

… There is a paucity of physiologically-based pharmacokinetic (PBPK) models for dabigatran
etexilate (DABE) and its metabolites with comprehensive mechanistic absorption. There are …

… in clinical practice. As a new oral reversible thrombin inhibitor, dabigatran etexilate is …
biotransformed into an active form of dabigatran, which directly inhibits thrombin (factor IIa) activity …

… Dabigatran etexilate (DABE) is a clinical probe substrate used to phenotype intestinal P-glycoprotein
(P-gp) function either in drug-drug interaction (DDI) or pharmacokinetic (PK) …

… 2.3 Dabigatran The thrombin inhibitor dabigatran is administered as a prodrug (dabigatran
etexilate) because active dabigatran is a poorly available hydrophilic zwitterion [3]. Other …

… , a thrombin inhibitor and P-gp substrate, making dabigatran exposure an intestinal P-gp
activity indicator. This study (NCT02568397) was conducted in 60 healthy subjects receiving a …

… thrombin generation, PT, aPTT, dPT, and TT after dabigatran … Considering that dabigatran
is a direct thrombin inhibitor, its … simvastatin clinically interacted with dabigatran etexilate and …

… One such DOAC is dabigatran etexilate, a direct oral thrombin inhibitor, which is approved
for the treatment of VTE and the prevention of recurrent VTE in adults based upon efficacy and …